Navigation Links
ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
Date:12/20/2007

IRVINE, Calif., Dec. 20 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced today the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Xibrom(TM) QD (once-daily). The Company is seeking approval for Xibrom QD as a treatment for inflammation, pain, and photophobia following cataract surgery.

Xibrom(TM) (bromfenac ophthalmic solution)

Xibrom is a topical non-steroidal anti-inflammatory compound for the treatment of ocular inflammation and pain. Xibrom, approved in 2005, is the first and only FDA-approved twice-daily NSAID for inflammation and reduction of pain following cataract surgery. Xibrom is the fastest growing ophthalmic product in 2007, according to IMS data. Xibrom, under a different trade name but identical formulation, was launched in Japan in 2000 by Senju Pharmaceuticals Co. Ltd. ISTA acquired U.S. marketing rights for Xibrom in 2002 and launched the product in the U.S. in 2005.

ABOUT ISTA PHARMACEUTICALS

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $3.2 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)... Benton Communications announces a highly effec... retailers struggling to make an economic recovery...2009 -- Flu fears is the type of challenge that co...m, according to Dr. David Benton, business growth ...rowth system – The Rfactor Intensive . &l...
(Date:11/25/2009)...v.25/PRNewswire-USNewswire/--Whenmostpeoplehearthe...rcanalsogivepatientsthehelptheyneed.TMJstandsforth...ible)contacts/connectswithyourskull(temporalbone)....nctionarepainwithchewing,clickingorpoppingofthejaw...including:headaches,fatigue,sleepdisturbances,irri...
(Date:11/25/2009)...if.,Nov.25/PRNewswire-FirstCall/-- OnyxPharmaceut...anywillhosttwoinvestoreventsinDecember: ,, AS...0a.m.ET ,, Principalinvestigatorswilldiscussd...d/orrefractorymultiplemyeloma,asfeaturedatthe51stA...ositioninNewOrleans,LA.Theteleconferencewillbegina...
(Date:11/25/2009).../PRNewswire/-SentinelleMedicalInc.,aleadingmanufac...arelaunchesasuiteofnewleadingedgeclinicalapplicati...hisyear,sRadiologicalSocietyofNorthAmerica(RSNA)an...allA).Theapplicationsleveragetheuniquehighqualityi...oilsandsupportmultipleimagingmodalitiesformulti-pa...
(Date:11/25/2009)...d.,Nov.25/PRNewswire-USNewswire/--AnarticlebyJanet...ationandResearch,titled"ADifficultBalance-PainMana...09issueofTheNewEnglandJournalofMedicine. ,, (Lo...DALOGO ) ,, Inthearticle,WoodcockdiscussesFDAef...forthosewhoneeditandmanagingtherisksposedbyvarious...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3
...ial role in determining the risk of having obese c...searchers at Boston University School of Public He...impact of this problem is more relevant in the dev...where food availability was either erratic or scar...
...etence of medical staff in the operating room, has... teamwork and increased awareness regarding operat...nd to rate the lowest with respect to teamwork. ...ironment. The SAQ, developed by a Johns Hopkins-le...
...ple sclerosis patients harbor immune cells that sp...known to cause certain cancers and mononucleosis. ...le in susceptibility to MS, the exact mechanism ha...is a result of the immune system attacking the bod...
...ones certain antidepressants and other medicines m... // But the bad news is that those medicines have ...e effects and they do not work as well as hormones...ciation. Hence the only way out would be sipping i...
...ance means worse care when it comes to preventive ...ly, even for the relatively well off people. // ... care internist in the Robert Wood Johnson Clinica...even though rates of use increase as income increa...
...ncer, explained that the women who receive abnorma...ey are not necessarily on the brink of cancer, // ...d their test results and ease their fears over cer... Nicola Gray, of Aberdeen University's departme...
Other Medicine News:Health News:Nurses Outsmart Surgeons When It Comes Safety And Team Wok 2Health News:Nurses Outsmart Surgeons When It Comes Safety And Team Wok 3Health News:EBV Might Trigger Multiple Sclerosis, Study 2Health News:EBV Might Trigger Multiple Sclerosis, Study 3Health News:EBV Might Trigger Multiple Sclerosis, Study 4Health News:Long Term Mediation Not Advisable To Treat Hot Flashes 2Health News:Lack Of Insurance Means Worse Care For Uninsured 2Health News:Lack Of Insurance Means Worse Care For Uninsured 3Health News:Study Shows That Women Need To Be Explained About The Smear Test 2
(Date:11/25/2009)...ortlinker.comannouncesthatanewmarketresearchreport...livery-USMarketTrends&Analysis http://www.rep...US-Market-Trends--Analysis.html ,, TheUSintran...rapeuticapplicationsfromthedeliveryofconventionall...uticdrugs.Thefutureofthetechnologyhingesontotheeff...
(Date:11/24/2009)... ,, WHAT:RomHoubens,aBelgianmanthoughttohavebee...lyfullyconsciousandawakeduringthattimeandwasthesub...asfeaturedinthesegmenttoillustratehowpeoplewithLoc...tion. ,, WHEN:GoodMorningAmerica-- Tuesday,Nove... ,, WHO:RomHoubenswasanengineeringstudentin198...
(Date:11/24/2009)...v.24/PRNewswire/-- EisaiInc.andPfizerIncannounced...cceptedforreviewEisai,sNewDrugApplication(NDA)foro...ase)tabletsforthetreatmentofmoderatetosevereAlzhei...ins23mgofdonepezilHClinanextendedrelease,matrix-ty...easeofthedrug.TheNDAisbasedonahead-to-headclinical...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Meat Dairy Wont Up Odds for Breast Cancer 55638 1Meat Dairy Wont Up Odds for Breast Cancer 55638 2Meat Dairy Wont Up Odds for Breast Cancer 55638 3WDIV TV Blue Cross Blue Shield of Michigan and The Parade Company Help Launch The Biggest Loser 3A Detroit Edition 55634 1WDIV TV Blue Cross Blue Shield of Michigan and The Parade Company Help Launch The Biggest Loser 3A Detroit Edition 55634 2Acoustic tweezers can position tiny objects 9729 1Acoustic tweezers can position tiny objects 9729 2Acoustic tweezers can position tiny objects 9729 3
... 19 Atritech, Inc. announced the upcoming,present...e WATCHMAN(R) Left,Atrial Appendage (LAA) Closure ...erapy, in patients with non-valvular atrial fibril...Breaking Clinical Trial session during,the I2 Summ.... The I2 Summit,is part of the Annual Meeting of ...
...Excess of $10 Million; Access Gains Second , Sour...pport , , DALLAS, and SEOUL, South Korea, Feb. 19...Board: ACCP) and JCOM Ltd , an affiliate of DO...ompany in the Republic of Korea, today announced t...er which JCOM and DONG-A will manufacture, develop...
Other Medicine Technology:Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting 2Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 2Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 3Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 4
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
Medicine Products: